MC225

Small molecule

UUniversity Medical Center Groningen

MC225 is one of 9 small molecule programs targeting Neurodegenerative Disease. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Neurodegenerative DiseaseActive, not recruiting

Neurodegenerative DiseasePhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

18 competitors in Neurodegenerative Disease

#DrugCompanyPhaseTrials

Nuplazid

AACADIA Pharmaceuticals Inc.

Approved

3 2

Robitussin

Aricept

1 4

Namenda

AbbVie

Preclinical

1 5

THK-5351

JJae Seung Kim

Phase 2

1 6

Intropin

Pfizer

Preclinical

—7

Citicoline

UUniversity of Texas Southwestern Medical Center

SNP318

1 9

MC225

UUniversity Medical Center Groningen

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Neurodegenerative Disease1 trial

[18F]MC225-PET in Neurodegenerative Disease

Unknown status·UUniversity Medical Center Groningen·Phase 1/2·NCT05853471·30 enrolled

Function1 trial

[18F]MC225 PET to Evaluate Gender Differences in BBB P-gp Function

Unknown status·UUniversity Medical Center Groningen·N/A·NCT05618119·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for MC225. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MC225 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MC225. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Medical Center Groningen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: UUniversity Medical Center Groningen

MC225

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Neurodegenerative Disease1 trial

Function1 trial

References

Drug Info

Quick Facts

Related News